Published in Cancer Res on November 15, 2000
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol (2001) 1.96
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol Cell Biol (2001) 1.61
Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J (2003) 1.59
MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer (2015) 1.47
c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol (2002) 1.43
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood (2015) 1.40
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A (2011) 1.13
c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem (2008) 1.12
Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08
c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J (2007) 1.08
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood (2009) 1.07
Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res (2011) 1.01
Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death Differ (2014) 0.99
c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J (2006) 0.97
Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia (2009) 0.91
Getting away with murder: how does the BCL-2 family of proteins kill with immunity? Ann N Y Acad Sci (2013) 0.91
The tumor suppressor protein HBP1 is a novel c-myc-binding protein that negatively regulates c-myc transcriptional activity. J Biol Chem (2009) 0.88
UVB upregulates the bax promoter in immortalized human keratinocytes via ROS induction of Id3. Exp Dermatol (2008) 0.88
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol (2011) 0.85
A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells. Neoplasia (2013) 0.84
Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice. Br J Cancer (2004) 0.83
Loss of BCL-2 in the progression of oral cancer is not attributable to mutations. J Clin Pathol (2005) 0.83
Activation of GluR6-containing kainate receptors induces ubiquitin-dependent Bcl-2 degradation via denitrosylation in the rat hippocampus after kainate treatment. J Biol Chem (2010) 0.81
c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade. Biochem J (2003) 0.80
Deciphering c-MYC-regulated genes in two distinct tissues. BMC Genomics (2011) 0.80
Repeated electroconvulsive seizure induces c-Myc down-regulation and Bad inactivation in the rat frontal cortex. Exp Mol Med (2008) 0.78
Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents. Sci Rep (2016) 0.77
Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma. Mol Cancer (2006) 0.77
C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling. J Mol Med (Berl) (2016) 0.76
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell (2016) 0.76
Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes (Basel) (2017) 0.75
Tetraarsenic oxide-mediated apoptosis in a cervical cancer cell line, SiHa. Cancer Res Treat (2005) 0.75
Gene Expression upon Proliferation and Differentiation of Hematopoietic Cells with Ph Chromosome ex vivo. Acta Naturae (2012) 0.75
An integrated method for the identification of novel genes related to oral cancer. PLoS One (2017) 0.75
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Mitochondria and apoptosis. Science (1998) 23.41
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 11.26
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Mitochondrial control of cell death. Nat Med (2000) 9.17
X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 8.26
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 7.31
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 7.24
Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A (1998) 6.69
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol (1999) 6.24
Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res (1993) 5.83
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (1998) 5.29
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science (1998) 4.84
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science (1986) 4.79
The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J (1997) 4.66
Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell (2001) 4.62
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell (1995) 4.53
Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science (1999) 4.43
Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell (1994) 4.32
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell (1996) 4.04
Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature (1993) 4.00
Anchorage dependence, integrins, and apoptosis. Cell (1994) 3.96
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J (1999) 3.51
Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci U S A (1997) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest (1996) 3.42
Caspase-9 can be activated without proteolytic processing. J Biol Chem (1999) 3.20
Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol (2000) 3.20
Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci U S A (1986) 3.19
Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell (1998) 3.09
FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (1995) 3.06
Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res (1994) 3.02
An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem (1999) 2.97
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med (2000) 2.96
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood (1993) 2.96
Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem (1998) 2.93
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature (1997) 2.93
BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J (1997) 2.91
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ (2005) 2.91
The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci U S A (1995) 2.90
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ (2006) 2.85
The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med (1997) 2.83
Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem (1996) 2.79
BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem (2000) 2.68
A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem (1998) 2.64
Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res (1994) 2.63
Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem (2000) 2.62
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med (2000) 2.62
Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol (2001) 2.61
Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med (1997) 2.59
Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol (1994) 2.57
The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med (1998) 2.51
Integrin activation by R-ras. Cell (1996) 2.50
Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene (1994) 2.49
An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 2.47
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 2.45
p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol (2000) 2.42
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene (1998) 2.39
Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science (1987) 2.36
Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem (1995) 2.35
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development (1996) 2.35
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood (1998) 2.31
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell Biol (1996) 2.24
Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci U S A (1996) 2.21
The AKT kinase is activated in multiple myeloma tumor cells. Blood (2001) 2.20
Age-associated cardiac dysfunction in Drosophila melanogaster. Circ Res (2001) 2.20
MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem (2000) 2.19
Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res (1997) 2.16
Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nat Neurosci (1998) 2.16
bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res (1992) 2.15
BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem (1996) 2.14
Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat Cell Biol (2000) 2.12
Identification of a phenotype-specific enhancer in the first intron of the rat collagen II gene. Proc Natl Acad Sci U S A (1987) 2.12
Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity (1998) 2.11
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood (2000) 2.11
Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J Biol Chem (1993) 2.07
Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med (2001) 2.07
p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. EMBO J (1998) 1.99
Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J (1999) 1.99